These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 7945408

  • 1. Antiproliferative activity of the topoisomerase I inhibitors topotecan and camptothecin, on sub- and postconfluent tumor cell cultures.
    Pizao PE, Smitskamp-Wilms E, Van Ark-Otte J, Beijnen JH, Peters GJ, Pinedo HM, Giaccone G.
    Biochem Pharmacol; 1994 Sep 15; 48(6):1145-54. PubMed ID: 7945408
    [Abstract] [Full Text] [Related]

  • 2. Homocamptothecin, an E-ring-modified camptothecin, exerts more potent antiproliferative activity than other topoisomerase I inhibitors in human colon cancers obtained from surgery and maintained in vitro under histotypical culture conditions.
    Philippart P, Harper L, Chaboteaux C, Decaestecker C, Bronckart Y, Gordover L, Lesueur-Ginot L, Malonne H, Lavergne O, Bigg DC, da Costa PM, Kiss R.
    Clin Cancer Res; 2000 Apr 15; 6(4):1557-62. PubMed ID: 10778989
    [Abstract] [Full Text] [Related]

  • 3. Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan.
    Sorensen M, Sehested M, Jensen PB.
    Br J Cancer; 1995 Aug 15; 72(2):399-404. PubMed ID: 7640225
    [Abstract] [Full Text] [Related]

  • 4. Topoisomerase I inhibitors. An overview of the camptothecin analogs.
    Burris HA, Fields SM.
    Hematol Oncol Clin North Am; 1994 Apr 15; 8(2):333-55. PubMed ID: 8040144
    [Abstract] [Full Text] [Related]

  • 5. In vivo antitumor activity of two new seven-substituted water-soluble camptothecin analogues.
    Emerson DL, Besterman JM, Brown HR, Evans MG, Leitner PP, Luzzio MJ, Shaffer JE, Sternbach DD, Uehling D, Vuong A.
    Cancer Res; 1995 Feb 01; 55(3):603-9. PubMed ID: 7834631
    [Abstract] [Full Text] [Related]

  • 6. Cross-resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations.
    Yang CJ, Horton JK, Cowan KH, Schneider E.
    Cancer Res; 1995 Sep 15; 55(18):4004-9. PubMed ID: 7664272
    [Abstract] [Full Text] [Related]

  • 7. Cytotoxic effects of anticancer agents on subconfluent and multilayered postconfluent cultures.
    Pizao PE, Peters GJ, Van Ark-Otte J, Smets LA, Smitskamp-Wilms E, Winograd B, Pinedo HM, Giaccone G.
    Eur J Cancer; 1993 Sep 15; 29A(11):1566-73. PubMed ID: 8217364
    [Abstract] [Full Text] [Related]

  • 8. Novel camptothecin derivative BNP1350 in experimental human ovarian cancer: determination of efficacy and possible mechanisms of resistance.
    Van Hattum AH, Schlüper HM, Hausheer FH, Pinedo HM, Boven E.
    Int J Cancer; 2002 Jul 01; 100(1):22-9. PubMed ID: 12115582
    [Abstract] [Full Text] [Related]

  • 9. Effects of topoisomerase I inhibition on the expression of topoisomerase II alpha measured with fluorescence image cytometry.
    Nicklee T, Crump M, Hedley DW.
    Cytometry; 1996 Nov 01; 25(3):205-10. PubMed ID: 8914817
    [Abstract] [Full Text] [Related]

  • 10. Interaction of ionizing radiation with topotecan in two human tumor cell lines.
    Marchesini R, Colombo A, Caserini C, Perego P, Supino R, Capranico G, Tronconi M, Zunino F.
    Int J Cancer; 1996 May 03; 66(3):342-6. PubMed ID: 8621255
    [Abstract] [Full Text] [Related]

  • 11. Gimatecan and other camptothecin derivatives poison Leishmania DNA-topoisomerase IB leading to a strong leishmanicidal effect.
    Prada CF, Alvarez-Velilla R, Balaña-Fouce R, Prieto C, Calvo-Álvarez E, Escudero-Martínez JM, Requena JM, Ordóñez C, Desideri A, Pérez-Pertejo Y, Reguera RM.
    Biochem Pharmacol; 2013 May 15; 85(10):1433-40. PubMed ID: 23466420
    [Abstract] [Full Text] [Related]

  • 12. Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor topotecan (SK&F 104864).
    Mattern MR, Hofmann GA, McCabe FL, Johnson RK.
    Cancer Res; 1991 Nov 01; 51(21):5813-6. PubMed ID: 1657371
    [Abstract] [Full Text] [Related]

  • 13. DNA topoisomerase I as a site of action for 10-hydroxycamptothecin in human promyelocytic leukemia cells.
    Ling YH, Andersson BS, Nelson JA.
    Cancer Biochem Biophys; 1990 Jan 01; 11(1):23-30. PubMed ID: 2159843
    [Abstract] [Full Text] [Related]

  • 14. Antitumor activity of 7-[2-(N-isopropylamino)ethyl]-(20S)-camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor.
    Lee JH, Lee JM, Kim JK, Ahn SK, Lee SJ, Kim MY, Jew SS, Park JG, Hong CI.
    Arch Pharm Res; 1998 Oct 01; 21(5):581-90. PubMed ID: 9875499
    [Abstract] [Full Text] [Related]

  • 15. Intermittent exposure of medulloblastoma cells to topotecan produces growth inhibition equivalent to continuous exposure.
    Danks MK, Pawlik CA, Whipple DO, Wolverton JS.
    Clin Cancer Res; 1997 Oct 01; 3(10):1731-8. PubMed ID: 9815557
    [Abstract] [Full Text] [Related]

  • 16. Cellular basis of antiproliferative and antitumor activity of the novel camptothecin derivative, gimatecan, in bladder carcinoma models.
    Ulivi P, Zoli W, Fabbri F, Brigliadori G, Ricotti L, Tesei A, Rosetti M, De Cesare M, Beretta GL, Corna E, Supino R, Zunino F.
    Neoplasia; 2005 Feb 01; 7(2):152-61. PubMed ID: 15802020
    [Abstract] [Full Text] [Related]

  • 17. Complex response of breast epithelial cell lines to topoisomerase inhibitors.
    Davis PL, Shaiu WL, Scott GL, Iglehart JD, Hsieh TS, Marks JR.
    Anticancer Res; 1998 Feb 01; 18(4C):2919-32. PubMed ID: 9713486
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Homocamptothecin, an E-ring-modified camptothecin analogue, generates new topoisomerase I-mediated DNA breaks.
    Bailly C, Lansiaux A, Dassonneville L, Demarquay D, Coulomb H, Huchet M, Lavergne O, Bigg DC.
    Biochemistry; 1999 Nov 23; 38(47):15556-63. PubMed ID: 10569939
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.